Physician

Ryan Francis Kendle, M.D.

According to 2025 Medicare claims, Ryan Kendle, M.D. (NPI: 1861719551) practices hematology/oncology in the Santa Maria-Santa Barbara, CA market, with the plurality of this provider's patient population coming from Santa Barbara, CA. This provider's primary affiliated billing organization is SANSUM CLINIC (NPI: 1932121514; TIN: 956419205) and primary practice location at 93105-4230. Kendle is affiliated with the Aledade A3299 CA MSSP Enhanced (ACO ID: A3299), participating under the MSSP model.

Kendle's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 443 traditional Medicare patients, billed 135,726 HCPCS/CPT codes, and received $2,817,814 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 582 prescription claims across 100 beneficiaries totaling $1,518,710 in drug costs, led by Lorbrena (Lorlatinib). DME data shows 23 claims. Open Payments data shows 44 records totaling $1,117. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $142,117 to $2,817,814. Similarly, Part D prescription costs have moved sharply higher in recent years, from $55,533 to $1,518,710. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	115	19,462	$142,117
2017	278	73,010	$1,383,795
2018	277	83,999	$1,345,847
2019	358	60,931	$1,094,814
2020	178	26,817	$508,811
2021	267	53,228	$732,910
2022	199	70,542	$1,385,057
2023	257	82,405	$1,768,983
2024	443	135,726	$2,817,814

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	27	98	$55,533
2017	87	474	$686,374
2018	120	808	$1,047,550
2019	141	907	$993,982
2020	95	450	$635,391
2021	83	400	$384,963
2022	83	471	$1,216,036
2023	88	350	$737,175
2024	100	582	$1,518,710

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	56	$1,003
2018	N/R	80	$11,393
2019	13	53	$6,094
2020	N/R	29	$2,341
2021	N/R	N/R	N/R
2022	N/R	29	$1,103
2023	N/R	N/R	N/R
2024	N/R	23	$725

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	101	292	$148
96413	Administration of chemotherapy into vein, 1 hour or less	92	272	$114
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	124	213	$95
96372	Injection of drug or substance under skin or into muscle	90	255	$12
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	79	110	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lorbrena	Lorlatinib	11	330	$239,650
Tagrisso	Osimertinib Mesylate	13	390	$211,034
Ibrance	Palbociclib	13	364	$205,318
Ninlaro	Ixazomib Citrate	12	266	$147,305
Lenalidomide	Lenalidomide	12	308	$117,069

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	12	$587
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	44	$1,117	EMD Serono, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ryan Francis Kendle, M.D.?

Tedicare shows public-source Medicare data for Ryan Francis Kendle, M.D. (NPI 1861719551), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ryan Francis Kendle, M.D. have ACO affiliation data?

Ryan Francis Kendle, M.D. is shown with ACO affiliation data for Aledade A3299 CA MSSP Enhanced (MSSP, ACO ID A3299).

What billing organization is linked to Ryan Francis Kendle, M.D.?

Ryan Francis Kendle, M.D. is linked to SANSUM CLINIC (billing NPI 1932121514) in the available physician profile data.

Does Ryan Francis Kendle, M.D. have Open Payments data?

Ryan Francis Kendle, M.D. has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.